Association of plasma and cortical amyloid beta is modulated by APOE ε4 status
作者
Shanker Swaminathan,Shannon L. Risacher,Karmen K. Yoder,John D. West,Li Shen,Sungeun Kim,Mark Inlow,Tatiana Foroud,William Jagust,Robert A. Koeppe,Chester A. Mathis,Leslie M. Shaw,John Q. Trojanowski,Holly Soares,Paul Aisen,Ronald C. Petersen,Michael W. Weiner,Andrew J. Saykin,Alzheimer's Disease Neuroimaging Initiative
BACKGROUND: Apolipoprotein E (APOE) ε4 allele's role as a modulator of the relationship between soluble plasma amyloid beta (Aβ) and fibrillar brain Aβ measured by Pittsburgh compound B positron emission tomography ([(11)C]PiB PET) has not been assessed. METHODS: Ninety-six Alzheimer's Disease Neuroimaging Initiative participants with [(11)C]PiB scans and plasma Aβ1-40 and Aβ1-42 measurements at the time of PET scanning were included. Regional and voxelwise analyses of [(11)C]PiB data were used to determine the influence of APOE ε4 allele on association of plasma Aβ1-40, Aβ1-42, and Aβ1-40/Aβ1-42 with [(11)C]PiB uptake. RESULTS: In APOE ε4- but not ε4+ participants, positive relationships between plasma Aβ1-40/Aβ1-42 and [(11)C]PiB uptake were observed. Modeling the interaction of APOE and plasma Aβ1-40/Aβ1-42 improved the explained variance in [(11)C]PiB binding compared with using APOE and plasma Aβ1-40/Aβ1-42 as separate terms. CONCLUSIONS: The results suggest that plasma Aβ is a potential Alzheimer's disease biomarker and highlight the importance of genetic variation in interpretation of plasma Aβ levels.